OM1 is an insights-driven technology and data company specializing in Personalized Medicine, Evidence Generation, and RWE Research powered by next-Gen A.I. platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. Our unprecedented innovation takes RWE from Bench-to-Practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research. We do things differently. We are pushing the boundaries of healthcare, reimagining how industry, providers, payers, and patients use real-world evidence. We are globally recognized for the integration of cutting-edge AI and data technologies. As pioneers in the field, our commitment to leveraging technology propels healthcare transformation, enhancing patient outcomes and setting new industry benchmarks.
OM1, Inc.的外部链接
31 Saint James Ave
Suite 1125
US，Massachusetts，Boston，02116
OM1, Inc.转发了
OM1, Inc. has added more than one million patients to its #mentalhealth network, expanding its ability to generate #realworldevidence for conditions such as #depression, #schizophrenia, and #bipolardisorder. #HealthData #RealWorldData #RWD #RWE #Neurology #ArtificialIntelligence #AI https://lnkd.in/ey8Cn74v
Traditional RCTs can’t keep pace with today’s personalized medicine demands. In this webinar, Nancy A. Dreyer and Eric Schrock will unpack how real-world evidence is accelerating development timelines, reducing site and patient burden, and delivering regulatory-grade insights using AI and deep longitudinal data. 📆 Save your spot: https://okt.to/qxLlpQ DIA #DrugDevelopment #MarketAccess #ClinicalResearch #LifeSciences #Pharma #DataAutomation
Across 500,000 patients with major depressive disorder, only 1% met both the classic and AI model definition of treatment-resistant depression (TRD). But how do we know which definition to use when looking for these patients who fall through the cracks? Carl D. Marci, M.D. explains why the AI definition is likely more accurate and very constant with what is seen in the literature. 📍Want to know more? Watch the full episode here 👉 https://okt.to/xqCjgT #AI #MentalHealth #TreatmentResistantDepression #TRD #Depression
📣 We're excited to announce the addition of over 1 million patients to our specialty mental health network, making it the largest, most clinically rich network of its kind. Now with over 6 million patients in our mental health network, including data from psychiatrists, other mental health providers, and clinical notes, this expansion boosts our ability to deliver timely, representative real-world evidence to our partners for better decision-making in life sciences and healthcare. 📍Read the full press release: https://okt.to/1Nkols Business Wire #MentalHealth #PersonalizedMedicine #AI #LifeScience
🇨🇦 OM1 is heading to Montreal for #ISPORAnnual! We're excited to connect with our fellow HEOR community and share real-world insights about suicidal ideation and GLP1 agonists, predictors of rheumatoid arthritis remission, and the latest in machine learning. 📍Discover how we’re advancing HEOR with AI and RWE: https://okt.to/gHSRwO ISPOR—The Professional Society for Health Economics and Outcomes Research Richard Jenkins Kathryn Starzyk Joseph Zabinski, Ph.D., M.E.M. Jessica Probst Chandrasekar Gopalakrishnan, MD, MPH David Giannino Bradley Snipes Todd Price Maria Demko #ISPOR2025 #HEOR #AI #MachineLearning #RealWorldEvidence
💡How can real-world data accelerate drug development? Join our upcoming webinar, where you'll learn from successful real-world case examples on how to: ✔️ Design fit-for-purpose RWE studies for regulatory and clinical impact ✔️ Reduce burden on sites and patients with data collection models ✔️ Derive new endpoints using AI and unstructured data 📅 Save your seat: https://okt.to/bNHgBw DIA Nancy A. Dreyer Eric Schrock #DrugDevelopment #MarketAccess #ClinicalResearch #LifeSciences #Pharma #DataAutomation
💡Last week, we shared the kinds of questions AI and enhanced real-world data help answer for commercial teams. This week, we're sharing what you can do with these insights. ✅ Profile patients and the physicians they see to uncover knowledge gaps and opportunities for outreach ✅ Heatmap potential patients and their physicians to identify ‘clusters’ remaining undiagnosed or untreated ✅ Implement PhenOM profile-based screening in health systems at the point of care or in direct-to-patient outreach 📍Watch the full webinar to learn how you can connect with the right patients at the right time: https://okt.to/maMXKe Fierce Pharma Joseph Zabinski, Ph.D., M.E.M. Kathryn Starzyk #FiercePharma #AI #MachineLearning #CommercialPharma
Excited to see the impact of real-world data in action. This collaboration with Nalu Medical, Inc. highlights how linking diverse data sources—like EHRs, claims, and device data—can provide powerful insights into patient outcomes and care patterns. Proud of the OM1 team for driving innovation in healthcare research! Carl D. Marci, M.D.
A newly published analysis found that chronic pain patients treated with Nalu peripheral nerve stimulation (PNS) had 50% lower medical costs. In this short video, a study author from OM1, Inc. explains how linking claims, EHR, pharmacy, and device data provides insight into healthcare utilization and opioid use before and after Nalu PNS. Watch the full clip and explore the peer-reviewed publication here: https://lnkd.in/ddJJPdEk #NaluMed #PNS #SCS #Neurostimulation #TreatMorePatients
OM1, Inc.转发了
We’re excited to announce our participation in the World Orphan Drug Congress in Boston from 22nd-24th April. Our US Rare Disease team, including Kate Hanman, Sarah Neubert and Caitlin Duffy would love to connect. Visit us at Booth 419 in the exhibition hall. Join us for our fireside chat on "Beyond the Buzz: Practical Applications of AI to Maximize Real-World Data" held on Wednesday 23rd April from 11:45 to 12:05 (ET) in Theater 3, Hall C. Dr. Joseph Zabinski, Ph.D., M.E.M. (VP and Head of Commercial Strategy & AI at OM1, Inc.) and Kate Hanman (our US Head of Rare Diseases), will explore using AI to address challenges like diagnostic coding and small patient numbers in the rare disease community. We look forward to seeing you there! #WODCUSA #RareDiseases #AI
🎙️🌟 NEW Behind the Insights: Decoding Treatment-Resistant Depression with Carl D. Marci, M.D. 🔎 What you'll learn in this episode: ✅ Why traditional methods often miss TRD patients ✅ How to bring “unseen” patients to light ✅ How unstructured clinical notes can help highlight “psychiatrist-attested TRD” 📍Watch the full episode here: https://okt.to/neCWK7 #AI #MentalHealth #TreatmentResistantDepression #TRD #Depression